Sagittal MRI of cardiac iron before (left) and after (right) therapy with the orally active iron chelating agent deferiprone in the same patient with homozygous β thalassemia whose liver histology and hepatic MRI are shown in Fig 3. Imhomogenity of cardiac signal in the MRI on the left is compatible with significant iron deposition, while improvement in signal intensity after nine months of chelating therapy indicates that the cardiac iron content is reduced compared with that of the previous study. (Reprinted with permission.192 )